Shannon K. Tyler, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2451 Fillingim St, Mastin Bldg., Mobile, AL 36617 Phone: 251-470-5890 Fax: 251-471-7925 |
Steven G Alsip, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 101 Memorial Hospital Dr Ste 200, Mobile, AL 36608 Phone: 251-414-5900 Fax: 251-675-5036 |
C Adrien Bodet Iii, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 101 Memorial Hospital Dr Ste 200, Mobile, AL 36608 Phone: 251-414-5922 Fax: 251-675-5036 |
John A. Vande Waa, DO, PHD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2451 Fillingim St, Mastin Bldg, Mobile, AL 36617 Phone: 251-470-5890 Fax: 251-471-7925 |
Amber Mahmood Bokhari, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2451 University Hospital Dr, Mastin 102, Mobile, AL 36617 Phone: 251-470-5890 Fax: 251-471-7925 |
News Archive
Clinical Data, Inc. today announced that it has raised gross proceeds of approximately $47.4 million through the public offering of 2,750,000 newly issued shares of its common stock at a price of $17.25 per share. All of the shares are being offered by Clinical Data, Inc.
Legend has it that Ralph Waldo Emerson once said, "Build a better mousetrap, and the world will beat a path to your door." University of Missouri researchers are doing just that, but instead of building mousetraps, the scientists are targeting cancer drugs. In a new study, MU medicinal chemists have taken an existing drug that is being developed for use in fighting certain types of cancer, added a special structure to it, and created a more potent, efficient weapon against cancer.
Significant new scientific evidence published over the last four years has prompted three major medical societies to change its guidance on who should get metabolic and bariatric surgery and which methods should be used.
Reuters reports that this development has to do with financial pragmatism - especially in GOP-led states that were at the forefront of opposition to the health law. The Associated Press provides a status check on Indiana's expansion request.
Harbor BioSciences, Inc. announced today that it has closed its previously announced sale of approximately $2.06 million of its common stock and warrants in a registered direct offering, issuance and sale to select investors.
› Verified 3 days ago